B. Mraz

Quality criteria for Real-World Data in pharmaceutical research and healthcare decision making. An Austrian Expert Consensus (Preprint)

G. Garhöfer, P. Klimek, H. Ostermann, 2021 .

Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: results of a pooled analysis of non-interventional studies.

L. Bergmann, A. Bamias, L. Albiges, 2015, European journal of cancer.

Real-World Evidence Data on Metastatic Renal-Cell Carcinoma Treatment in Austria: The RELACS Study.

M. Mitterberger, T. Bauernhofer, M. Kretz, 2019, Clinical genitourinary cancer.

Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2− advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT

R. Greil, M. Gnant, G. Steger, 2020, Breast.

Quality Criteria for Real-world Data in Pharmaceutical Research and Health Care Decision-making: Austrian Expert Consensus

G. Garhöfer, P. Klimek, H. Ostermann, 2021, JMIR medical informatics.

Economic impact of industry-sponsored clinical trials of pharmaceutical products in Austria

S. Kaehler, E. Walter, I. Presch, 2020, Journal of medical economics.

Dabrafenib plus trametinib in unselected advanced BRAF V600–mut melanoma: a non-interventional, multicenter, prospective trial

E. Richtig, C. Hoeller, P. Koelblinger, 2023, Melanoma research.